Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Key Takeaway: Vertex Pharmaceuticals presented new data on CASGEVY® at the European Hematology Association Congress. This included the first European presentation of data in children aged 5-11. Additionally, the company announced further global regulatory submissions related to CASGEVY®.